Harmony Biosciences price target raised to $55 from $54 at Deutsche Bank

Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $55 from $54 and keeps a Buy rating on the shares. The firm says the company has a key clinical catalyst this quarter with readout of the Phase 3 RECONNECT trial in Fragile X syndrome. The data could materially drive shares if positive and “presents asymmetric risk-reward to the upside,” the analyst tells investors in a research note.